Imaging of Lung Cancer in the Era of Molecular Medicine

被引：36
作者：
Nishino, Mizuki [1 ,3 ]
Jackman, David M. [2 ]
Hatabu, Hiroto [3 ]
Jaenne, Pasi A. [2 ]
Johnson, Bruce E. [2 ]
Van den Abbeele, Annick D. [1 ,3 ]
机构：
[1] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA
来源：
ACADEMIC RADIOLOGY | 2011年 / 18卷 / 04期
关键词：
Lung cancer; targeted therapy; computed tomography; dynamic-contrast-enhanced magnetic resonance imaging; positron emission tomography; GROWTH-FACTOR-RECEPTOR; SOLITARY PULMONARY NODULES; POSITRON-EMISSION-TOMOGRAPHY; PREVIOUSLY TREATED PATIENTS; TYROSINE KINASE INHIBITORS; CONTRAST-ENHANCED MRI; PHASE-II TRIAL; TUMOR RESPONSE; ACQUIRED-RESISTANCE; KRAS MUTATIONS;
D O I：
10.1016/j.acra.2010.10.020
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Recent discoveries characterizing the molecular basis of lung cancer brought fundamental changes in lung cancer treatment. The authors review the molecular pathogenesis of lung cancer, including genomic abnormalities, targeted therapies, and resistance mechanisms, and discuss lung cancer imaging with novel techniques. Knowledge of the molecular basis of lung cancer is essential for radiologists to properly interpret imaging and assess response to therapy. Quantitative and functional imaging helps assessing the biologic behavior of lung cancer.
引用
收藏
页码：424 / 436
页数：13
相关论文
共 97 条
  • [1] ALBERTI W, 1995, BRIT MED J, V311, P899
  • [2] American Cancer Society, 2009, CANC FACT FIG
  • [3] A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
    Asahina, H.
    Yamazaki, K.
    Kinoshita, I.
    Sukoh, N.
    Harada, M.
    Yokouchi, H.
    Ishida, T.
    Ogura, S.
    Kojima, T.
    Okamoto, Y.
    Fujita, Y.
    Dosaka-Akita, H.
    Isobe, H.
    Nishimura, M.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (08) : 998 - 1004
  • [4] SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas
    Bass, Adam J.
    Watanabe, Hideo
    Mermel, Craig H.
    Yu, Soyoung
    Perner, Sven
    Verhaak, Roel G.
    Kim, So Young
    Wardwell, Leslie
    Tamayo, Pablo
    Gat-Viks, Irit
    Ramos, Alex H.
    Woo, Michele S.
    Weir, Barbara A.
    Getz, Gad
    Beroukhim, Rameen
    O'Kelly, Michael
    Dutt, Amit
    Rozenblatt-Rosen, Orit
    Dziunycz, Piotr
    Komisarof, Justin
    Chirieac, Lucian R.
    LaFargue, Christopher J.
    Scheble, Veit
    Wilbertz, Theresia
    Ma, Changqing
    Rao, Shilpa
    Nakagawa, Hiroshi
    Stairs, Douglas B.
    Lin, Lin
    Giordano, Thomas J.
    Wagner, Patrick
    Minna, John D.
    Gazdar, Adi F.
    Zhu, Chang Qi
    Brose, Marcia S.
    Cecconello, Ivan
    Ribeiro, Ulysses, Jr.
    Marie, Suely K.
    Dahl, Olav
    Shivdasani, Ramesh A.
    Tsao, Ming-Sound
    Rubin, Mark A.
    Wong, Kwok K.
    Regev, Aviv
    Hahn, William C.
    Beer, David G.
    Rustgi, Anil K.
    Meyerson, Matthew
    [J]. NATURE GENETICS, 2009, 41 (11) : 1238 - U105
  • [5] MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
    Bean, James
    Brennan, Cameron
    Shih, Jin-Yuan
    Riely, Gregory
    Viale, Agnes
    Wang, Lu
    Chitale, Dhananjay
    Motoi, Noriko
    Szoke, Janos
    Broderick, Stephen
    Balak, Marissa
    Chang, Wen-Cheng
    Yu, Chong-Jen
    Gazdar, Adi
    Pass, Harvey
    Rusch, Valerie
    Gerald, William
    Huang, Shiu-Feng
    Yang, Pan-Chyr
    Miller, Vincent
    Ladany, Marc
    Yang, Chih-Hsin
    Pao, William
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) : 20932 - 20937
  • [6] Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
    Bell, DW
    Gore, I
    Okimoto, RA
    Godin-Heymann, N
    Sordella, R
    Mulloy, R
    Sharma, SV
    Brannigan, BW
    Mohapatra, G
    Settleman, J
    Haber, DA
    [J]. NATURE GENETICS, 2005, 37 (12) : 1315 - 1316
  • [7] Brabender J, 2001, CLIN CANCER RES, V7, P1850
  • [8] Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results
    Breathnach, OS
    Freidlin, B
    Conley, B
    Green, MR
    Johnson, DH
    Gandara, DR
    O'Connell, M
    Shepherd, FA
    Johnson, BE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) : 1734 - 1742
  • [9] Buck AK, 2002, CANCER RES, V62, P3331
  • [10] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
    Cappuzzo, F
    Hirsch, FR
    Rossi, E
    Bartolini, S
    Ceresoli, GL
    Bemis, L
    Haney, J
    Witta, S
    Danenberg, K
    Domenichini, I
    Ludovini, V
    Magrini, E
    Gregorc, V
    Doglioni, C
    Sidoni, A
    Tonato, M
    Franklin, WA
    Crino, L
    Bunn, PA
    Varella-Garcia, M
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09): : 643 - 655
12345678910